Key result
High-dose cisplatin therapy (OR 2.15; 95% CI 1.50-3.07), cardiac disease, and hypertension were independent risk factors for cisplatin-induced nephrotoxicity.
Why the study?
Cisplatin-induced nephrotoxicity is a concern in cisplatin-based chemotherapy, prompting the need to identify potential risk factors.
Observational (n=762)
Yes
Odds Ratio: 2.15 (95% CI 1.5–3.07)
p-value: p=<0.01
Comorbid cardiac disease and hypertension are independent risk factors for cisplatin-induced nephrotoxicity, highlighting the need for close monitoring in these patients.
Cardiac disease and hypertension were associated with cisplatin nephrotoxicity; hypothesis-generating for risk-stratified monitoring pending validation.
INTRODUCTION: Cisplatin (CDDP)-induced nephrotoxicity is a concern in CDDP-based chemotherapy. The goal of this multicenter retrospective study was to identify potential risk factors for CDDP nephrotoxicity. METHODS: Clinical data were reviewed for 762 patients who underwent chemotherapy including CDDP ≥60 mg/m2 per day from Spring 2014 to September 2016. CDDP nephrotoxicity was defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events for acute kidney injury. Univariate and multivariate logistic regression analyses were performed to identify risk factors for CDDP nephrotoxicity. RESULTS: CDDP nephrotoxicity was observed in 165 patients (21.7%). Multivariate analysis showed a significantly higher rate of CDDP nephrotoxicity in patients with cardiac disease (odds ratio [OR]: 2.05, 95% confidence interval [CI]: 1.07-3.93, p = 0.03), hypertension (OR: 1.57, 95% CI: 1.06-2.32, p = 0.02), and high-dose CDDP therapy (OR: 2.15, 95% CI: 1.50-3.07, p < 0.01). Magnesium (Mg) supplementation (OR: 0.65, 95% CI: 0.45-0.93, p = 0.02) and diuretic use (OR: 0.22, 95% CI: 0.08-0.63, p < 0.01) were also independent risk factors for CDDP nephrotoxicity. CONCLUSIONS: Our results suggest that high-dose CDDP and comorbidities of cardiac disease and hypertension are independent risk factors for CDDP nephrotoxicity. Therefore, close monitoring of serum creatinine values during CDDP treatment is recommended for patients with these risk factors. In addition, Mg supplementation and administration of diuretics might be effective for prevention of CDDP nephrotoxicity.
No takes yet. Share an insight, caveat, or question.
Miyoshi et al. (2020) conducted an observational in Cisplatin-induced nephrotoxicity (n=762). High-dose CDDP therapy, cardiac disease, and hypertension vs. Patients without these risk factors was evaluated on CDDP nephrotoxicity (OR 2.15, 95% CI 1.50-3.07, p=<0.01). High-dose cisplatin therapy (OR 2.15; 95% CI 1.50-3.07), cardiac disease, and hypertension were independent risk factors for cisplatin-induced nephrotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: